€441.00
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 0.680% | -0.260% | 5.063% | 36.765% | 18.660% | 160.947% | 178.409% |
| Exact Sciences | -0.340% | 4.093% | -4.105% | -53.295% | -41.369% | -61.160% | -60.808% |
| Incyte Corp. | -3.170% | -6.692% | 3.154% | -3.682% | -3.172% | -22.005% | -26.854% |
| Regeneron Pharmaceuticals Inc. | -2.340% | -2.761% | 7.617% | 47.496% | 21.881% | 97.561% | 244.193% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.
Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.
The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.
Comments
News
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
The stock market has its ups and downs -- and if you stay invested for decades, you will likely experience your fair share of both bull and bear markets. At the same time, by investing in a diverse
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years.
These changes should present great opportunities
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a